Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,782,101
  • Shares Outstanding, K 113,072
  • Annual Sales, $ 219,750 K
  • Annual Income, $ -886,120 K
  • 60-Month Beta 2.22
  • Price/Sales 55.16
  • Price/Cash Flow N/A
  • Price/Book 8.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.87
  • Number of Estimates 7
  • High Estimate -1.61
  • Low Estimate -2.00
  • Prior Year -1.73
  • Growth Rate Est. (year over year) -8.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.97 +22.63%
on 03/13/20
134.26 -22.39%
on 03/16/20
-8.29 (-7.37%)
since 02/27/20
3-Month
84.97 +22.63%
on 03/13/20
134.51 -22.53%
on 02/12/20
-13.34 (-11.35%)
since 12/27/19
52-Week
65.81 +58.33%
on 05/20/19
134.51 -22.53%
on 02/12/20
+17.85 (+20.67%)
since 03/27/19

Most Recent Stories

More News
Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO(R) (patisiran), the First-in-Class 'Gene-Silencing' RNAi Therapeutic

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases, today announced an exclusive Distribution...

ALNY : 104.20 (-2.81%)
Look for Shares of Alnylam Pharmace to Potentially Rebound after Yesterday's 7.58% Sell Off

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $85.01 to a high of $97.50. Yesterday, the shares fell 7.6%, which took the trading range below the 3-day low of...

ALNY : 104.20 (-2.81%)
Alnylam Pharmace Shares Down 10.4% Since SmarTrend's Sell Call (ALNY)

SmarTrend identified a Downtrend for Alnylam Pharmace (NASDAQ:ALNY) on February 26th, 2020 at $118.04. In approximately 2 weeks, Alnylam Pharmace has returned 10.41% as of today's recent price of $105.75....

ALNY : 104.20 (-2.81%)
Why Is Alnylam (ALNY) Down 7% Since Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALNY : 104.20 (-2.81%)
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals

The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals

MRNA : 30.05 (+7.55%)
ALNY : 104.20 (-2.81%)
INO : 8.32 (+16.36%)
VIR : 34.30 (+7.19%)
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

GILD : 72.85 (-1.37%)
ALNY : 104.20 (-2.81%)
ABBV : 72.67 (-1.57%)
VIR : 34.30 (+7.19%)
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners

U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.

MRNA : 30.05 (+7.55%)
ALNY : 104.20 (-2.81%)
INO : 8.32 (+16.36%)
VIR : 34.30 (+7.19%)
Alnylam's Givlaari Gets Approval in Europe for Rare Disease

Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.

RHHBY : 38.9650 (+0.48%)
ALNY : 104.20 (-2.81%)
NVS : 79.28 (-0.58%)
IONS : 49.41 (-0.68%)
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

BIIB : 296.75 (-2.69%)
GILD : 72.85 (-1.37%)
INCY : 68.96 (-5.60%)
ALNY : 104.20 (-2.81%)
SGMO : 6.34 (-4.80%)
BHVN : 35.28 (-1.48%)
FTSV : 94.55 (+0.08%)
Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

---- Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option for 50-50 participation

VIR : 34.30 (+7.19%)
ALNY : 104.20 (-2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 111.43
1st Resistance Point 107.81
Last Price 104.20
1st Support Level 99.60
2nd Support Level 95.01

See More

52-Week High 134.51
Fibonacci 61.8% 108.27
Last Price 104.20
Fibonacci 50% 100.16
Fibonacci 38.2% 92.05
52-Week Low 65.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar